Oncology

News

Astellas suffers pancreatic cancer failure with Vyloy

Astellas' effort to expand the reach of its first-in-class claudin 18.2 drug Vyloy into pancreatic cancer has had a major setback.

News

Kelun gets world-first approval for TROP2 ADC

Kelun-Biotech has picked up another world-first approval for its TROP2-targeting ADC sac-TMT in non-small cell lung cancer.

News

Regeneron's Libtayo stakes out new territory in skin cancer

Regeneron's Libtayo has become the first checkpoint inhibitor to be cleared by the FDA as an adjuvant treatment for cutaneous squamous cell carcinoma.

Digital

Agentic AI buoys all stakeholders in oncology, with Eron Kel...

At LSX 2025, Eron Kelly, CEO of Concert AI, discussed the work his Boston-based start-up is doing in oncology.

News

Sanofi, Orano cue up filings for GEP-NET radioligand therapy

Clinical results with GEP-NET radioligand therapy AlphaMedix, a possible rival to Novartis' Lutathera, could lead to regulatory filings.

Oncology

Pre-ESMO insights: Corcept on platinum-resistant ovarian can...

pharmaphorum speaks with Corcept Therapeutics about its presentation of data in platinum-resistant ovarian cancer at both ASCO and ahead of ESMO 2025.

Astellas suffers pancreatic cancer failure with Vyloy

Kelun gets world-first approval for TROP2 ADC

Regeneron's Libtayo stakes out new territory in skin cancer

Agentic AI buoys all stakeholders in oncology, with Eron Kel...

Sanofi, Orano cue up filings for GEP-NET radioligand therapy

Pre-ESMO insights: Corcept on platinum-resistant ovarian can...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Oncology

Editor's Picks